Zobrazeno 241 - 250
of 3 422
pro vyhledávání: '"33"'
Autor:
Gregg JL; University of Pittsburgh, Department of Urology and University of Pittsburgh Cancer Institute., Turner RM 2nd; University of Pittsburgh, Department of Urology and University of Pittsburgh Cancer Institute., Chang G; University of Pittsburgh, Department of Urology and University of Pittsburgh Cancer Institute., Joshi D; University of Pittsburgh, Department of Urology and University of Pittsburgh Cancer Institute., Zhan Y; University of Massachusetts, Department of Surgery., Chen L; University of Pittsburgh, Department of Urology and University of Pittsburgh Cancer Institute., Maranchie JK; University of Pittsburgh, Department of Urology and University of Pittsburgh Cancer Institute.
Publikováno v:
Cancer research [Cancer Res] 2014 Jul 01; Vol. 74 (13), pp. 3501-3511. Date of Electronic Publication: 2014 Apr 22.
Autor:
YX Nagarwala, Kristi McIntyre, Joyce A. O'Shaughnessy, RC Gagnon, JM Mahoney, Jenny C. Chang, Virginia Espina, CR Osborne, Lance A. Liotta, L Krekow, Frankie A. Holmes, Michael A. Danso
Publikováno v:
Cancer Research. 71:P5-13
Background 15% of curative HER2−positive patients (pts) treated with standard trastuzumab (T)-based chemotherapy regimens recur. Our prior report (ASCO 2011 #506 using only data from paired samples N=49) identified major pathways of resistance: aut
Autor:
Cieply B; Authors' Affiliations: Mary Babb Randolph Cancer Center and Department of Biochemistry, West Virginia University, Morgantown; Department of Biochemistry and Microbiology, Marshall University, Huntington, West Virginia; and Departments of Biochemistry/Molecular Genetics and Obstetrics/Gynecology, University of Colorado, Denver, Colorado., Farris J, Denvir J, Ford HL, Frisch SM
Publikováno v:
Cancer research [Cancer Res] 2013 Oct 15; Vol. 73 (20), pp. 6299-309. Date of Electronic Publication: 2013 Aug 13.
Autor:
Balko JM; Authors' Affiliations: Departments of Medicine and Cancer Biology; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú; and Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire., Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL
Publikováno v:
Cancer research [Cancer Res] 2013 Oct 15; Vol. 73 (20), pp. 6346-58. Date of Electronic Publication: 2013 Aug 21.
Autor:
Lin C; Authors' Affiliations: Division of Dermatology, Department of Medicine, Departments of Obstetrics and Gynecology, and Pathology and Immunology, Washington University in St. Louis, St. Louis, Missouri; and Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Yin Y, Stemler K, Humphrey P, Kibel AS, Mysorekar IU, Ma L
Publikováno v:
Cancer research [Cancer Res] 2013 Oct 01; Vol. 73 (19), pp. 5914-25. Date of Electronic Publication: 2013 Aug 08.
Autor:
Ana C Garrido-Castro, Noah Graham, Kevin Bi, Jihye Park, Jingxin Fu, Tanya Keenan, Edward Thomas Richardson, Ricardo Pastorello, Paulina Lange, Victoria Attaya, Robert Wesolowski, Natalie Sinclair, Zarah Lucas, Steve Lo, Nadine Tung, Meredith Faggen, Peter A Kaufman, Caroline C Block, Fred Briccetti, Madhavi Toke, Wendy Chen, Kai Wucherpfennig, Sascha Marx, Ye Tian, Judith Agudo, Jennifer L Guerriero, Stuart Schnitt, Nancy U Lin, Eric P Winer, Elizabeth A Mittendorf, Nabihah Tayob, Eliezer Van Allen, Sara M Tolaney
Publikováno v:
Cancer Research. 82:P2-14
Background: Platinum agents induce DNA crosslinking and cause accumulation of genotoxic stress, which leads to immune activation via IFN-γ signaling, making the combination with nivolumab (PD-1 antibody) an attractive strategy to enhance the benefit
Autor:
Sophie Martin, Carole Pflumio, Philippe Trensz, Frederique Schaff-Wendling, Michal Kalish, Cathie Fischbach, Laure Pierard, Jean-Marc Limacher, Michel Velten, Thierry Petit
Publikováno v:
Cancer Research. 82:P1-17
Background: The impact of some medical decisions hurriedly taken during the COVID-19 first wave remains unknown. We tried to assess the consequences of one of these precautionary measures, namely the interruption of a 4/6 cyclin D-dependent kinase in
Autor:
Jennifer Y Sheng, Claire F Snyder, Katherine C Smith, Jennifer DeSanto, Nancy Mayonado, Susan Rall, Sharon White, Amanda L Blackford, Fabian M Johnston, Robert L Joyner, Joan Mischtschuk, Kimberly S Peairs, Elissa Thorner, Phuoc T Tran, Antonio C Wolff, Youngjee Choi
Publikováno v:
Cancer Research. 82:P4-11
Background: From a randomized, controlled trial of survivorship care plan (SCP) delivery, we examined whether cancer-related tests not specified in participants’ SCPs, but conducted after SCP receipt, were appropriate or consistent with overuse (CW
Autor:
Stuart A McIntosh, Charlotte E Coles, Carmel Conefrey, David Dodwell, Kenneth Elder, Jessica Foster, Claire Gaunt, Amanda Kirkham, Iain Lyburn, Jenna Morgan, Sangeetha Paramasivan, Sarah Pinder, Sarah Pirrie, Shelley Potter, Tracy Roberts, Nisha Sharma, Hilary Stobart, Elizabeth Southgate, Sian Taylor-Phillips, Matthew Wallis, Daniel Rea
Publikováno v:
Cancer Research. 82:OT1-06
Background:. Mammographic screening programmes have been shown to reduce breast cancer mortality. However, they detect many small tumours with favourable biological features which may not progress during a woman’s lifetime. These are treated with s
Autor:
Pathmanathan Rajadurai, Tatiana Semiglazova, Alinta Hegmane, Fadi El Karak, Joanne W Chiu, Sudeep Gupta, Hamdy A Azim, Josef JEM Kitzen, Antoine Arnaud, Sina Haftchenary, Jiwen Wu, Lakshmi Menon-Singh, LaTonya Smith, Lyudmila Zhukova
Publikováno v:
Cancer Research. 82:P5-13
Introduction: PIK3CA mutations (mut) occur in ~40% of patients (pts) with HR+, HER2- ABC, and lead to phosphatidylinositol 3-kinase (PI3K) pathway hyperactivation, endocrine resistance, and poor survival in advanced disease. Alpelisib, an α-selectiv